Abstract | BACKGROUND: There is a need to assess whether human immunodeficiency virus (HIV)-infected patients are more likely than noninfected individuals to have any of the specific lipoprotein combination profiles identified as the best predictors of future cardiovascular disease in the general population. METHODS: RESULTS: The highly atherogenic lipoprotein phenotypes were similarly frequent in both groups. There was a nonsignificant increased risk of dyslipidemia with longer exposure to any of the ART drug classes, although this hazard seems to be greater in patients with central fat accumulation. CONCLUSIONS: No evidence of increased risk for certain highly atherogenic lipoprotein phenotypes in HIV-infected patients was found. More than one pathogenic mechanism for ART-associated dyslipidemia is postulated.
|
Authors | Andrés Catzin-Kuhlmann, Lilia Castillo-Martínez, Eloisa Colín-Ramírez, Victoria Valles, Carlos A Aguilar-Salinas, Juan Sierra, Juan J Calva |
Journal | Archives of medical research
(Arch Med Res)
Vol. 39
Issue 1
Pg. 84-91
(Jan 2008)
ISSN: 0188-4409 [Print] United States |
PMID | 18068000
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- Apolipoprotein A-I
- Apolipoproteins B
|
Topics |
- Adult
- Anti-HIV Agents
(therapeutic use)
- Apolipoprotein A-I
(blood)
- Apolipoproteins B
(blood)
- Atherosclerosis
(diagnosis, epidemiology)
- Female
- HIV Infections
(complications, drug therapy)
- Humans
- Hypertriglyceridemia
(diagnosis, epidemiology)
- Hypoalphalipoproteinemias
(diagnosis, epidemiology)
- Male
- Mexico
(epidemiology)
- Middle Aged
- Phenotype
- Prevalence
- Risk
|